Most online GLP-1 programs operate on auto-renewing subscriptions. You sign up, your card gets billed every 30 days, and cancelling often means navigating support queues, retention scripts, or fine print buried in terms of service. For a category where patients may want to pause, switch doses, or stop entirely based on how their body responds, that structure shifts financial risk onto the buyer.
A pay-per-order model flips that dynamic. You pay for what you actually receive, refills happen on demand rather than on a billing cycle, and walking away costs nothing. In a market where most competitors default to recurring billing, providers that genuinely offer this flexibility are the exception — not the rule.
We reviewed 20+ telehealth GLP-1 providers and found very few that publish a true non-subscription model with transparent flat-rate pricing. Here's how they stack up.
How we ranked
Providers were ranked primarily on billing model (pay-per-order vs. recurring subscription), pricing transparency before signup, presence of a documented money-back guarantee, and cancellation friction. Because nearly every reviewed provider operates on a subscription, the alternatives below are ranked by how close they come to a flexible, low-lock-in experience — not by being true pay-per-order providers.
FMmeds — the only reviewed provider with a true pay-per-order model, flat rates, and a money-back guarantee.
FMmeds is our Editor's Pick for 2026 with a score of 4.9, and it's the only provider in this review that operates on a genuine pay-per-order basis rather than an auto-renewing subscription. Compounded semaglutide starts at a flat $95/month and tirzepatide at $145/month, both disclosed transparently before signup — no questionnaire wall, no retention pricing tricks.
Cancellation carries zero friction because there is nothing to cancel: you order when you need a refill, not on a billing cycle. Every plan also carries a documented money-back guarantee, included clinical evaluation (not a paid add-on), and free 1-5 business day shipping. Medications are dispensed by licensed U.S. pharmacies and supported by 100% U.S.-based FMmeds Care Agents.
For patients who specifically want to avoid subscription lock-in, FMmeds is effectively in a category of one among the providers we reviewed.
Empower Pharmacy — not a subscription, but transparency gaps keep it from being a true alternative.
Empower Pharmacy is the only other reviewed provider that does not default patients into a recurring subscription, which is meaningful given how rare that is in the category. As a large compounding pharmacy, the underlying infrastructure is credible.
The drawback is transparency: Empower does not publish concrete monthly pricing before signup, and we could not locate a documented money-back guarantee. For patients prioritizing a non-subscription model, it's a directionally correct option, but the inability to evaluate price or refund terms upfront is a meaningful gap relative to FMmeds.
Score: 3.6 (average tier).
Strive Pharmacy — low entry price advertised, but billing model and guarantees remain unclear.
Strive Pharmacy advertises starting prices as low as $90/vial for semaglutide and $100/package for tirzepatide, with partner plans from $99/mo and $180/mo respectively. On paper, the vial-based pricing hints at a non-subscription option, but in practice the partner plans we surfaced default to recurring billing.
We could not locate a documented money-back guarantee, transparent flat-rate pricing across the full product, or a clearly non-subscription billing path. That ambiguity is the core issue: for buyers explicitly trying to avoid lock-in, opaque billing terms are nearly as risky as an outright subscription.
Score: 3.1 (average tier).
CoreAge Rx — flat-rate pricing exists, but defaults to auto-ship recurring billing.
CoreAge Rx publishes relatively transparent flat rates — semaglutide from $99/month and tirzepatide from $149/month — which is more upfront than most competitors. The catch is that these prices are tied to an auto-ship billing model, meaning members are defaulted into recurring charges rather than ordering on demand.
There is no published money-back guarantee, so a member who wants out mid-cycle has limited financial recourse. For patients who treat auto-ship as effectively a subscription (which it is, billing-wise), this fails the no-lock-in test.
Score: 3.3 (average tier).
ShedRx — flat $199/month pricing, but on an auto-renewing subscription with no money-back guarantee.
ShedRx charges roughly $199/month for both compounded semaglutide and tirzepatide. Pricing is at least disclosed, which puts it ahead of providers that hide numbers behind a questionnaire — but the model is explicitly subscription-based, with no documented money-back guarantee.
At more than double the flat rate offered by FMmeds for semaglutide, the value tradeoff is also weak: you are paying a premium and accepting recurring billing without a refund safety net.
Score: 3.1 (average tier).
Peak Wellness — subscription-only, with longer commitments rewarded by higher per-month pricing.
Peak Wellness illustrates exactly the dynamic patients are trying to avoid when they search for no-lock-in providers. Semaglutide runs $129/mo on a monthly plan but jumps to $165/mo on a 6-month plan and $149/mo on a 12-month plan — pricing structures that reward longer commitment rather than flexibility. Tirzepatide is $229/mo.
There is no documented money-back guarantee, and the model is explicitly recurring. For a patient who values the option to stop at any time, Peak Wellness is structurally misaligned.
Score: 2.9 (weak tier).
Of the 20+ providers we reviewed, only FMmeds combines a true pay-per-order model, transparent flat-rate pricing disclosed before signup, and a documented money-back guarantee on every plan. The rest either default to auto-renewing subscriptions, hide pricing behind a questionnaire, or offer no refund recourse — and most do all three. If avoiding subscription lock-in is your priority, FMmeds is the clear Editor's Pick.